S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61

Mersana Therapeutics Stock Forecast, Price & News

+0.09 (+1.83%)
(As of 06/24/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
5.26 million shs
Average Volume
1.20 million shs
Market Capitalization
$484.95 million
P/E Ratio
Dividend Yield
Price Target
30 days | 90 days | 365 days | Advanced Chart

Receive MRSN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mersana Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MRSN Stock Forecast (MarketRank)

Overall MarketRank

2.40 out of 5 stars

Medical Sector

194th out of 1,417 stocks

Pharmaceutical Preparations Industry

79th out of 675 stocks

Analyst Opinion: 3.5Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -
Mersana Therapeutics logo

About Mersana Therapeutics (NASDAQ:MRSN)

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development candidate. It has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.

MRSN Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
4 Analysts


Net Income
$-170.06 million
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
$40 thousand
Price / Sales
Book Value
$1.69 per share


Free Float
Market Cap
$484.95 million
Not Optionable

Mersana Therapeutics Frequently Asked Questions

Should I buy or sell Mersana Therapeutics stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Mersana Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Mersana Therapeutics stock.
View analyst ratings for Mersana Therapeutics
or view top-rated stocks.

What is Mersana Therapeutics' stock price forecast for 2022?

4 equities research analysts have issued 12 month price objectives for Mersana Therapeutics' stock. Their MRSN stock forecasts range from $16.00 to $32.00. On average, they expect Mersana Therapeutics' share price to reach $21.25 in the next twelve months. This suggests a possible upside of 325.0% from the stock's current price.
View analysts' price targets for Mersana Therapeutics
or view top-rated stocks among Wall Street analysts.

How has Mersana Therapeutics' stock performed in 2022?

Mersana Therapeutics' stock was trading at $6.22 on January 1st, 2022. Since then, MRSN stock has decreased by 19.6% and is now trading at $5.00.
View the best growth stocks for 2022 here

Are investors shorting Mersana Therapeutics?

Mersana Therapeutics saw a increase in short interest in May. As of May 31st, there was short interest totaling 5,870,000 shares, an increase of 26.5% from the May 15th total of 4,640,000 shares. Based on an average trading volume of 1,480,000 shares, the days-to-cover ratio is presently 4.0 days.
View Mersana Therapeutics' Short Interest

When is Mersana Therapeutics' next earnings date?

Mersana Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, August 5th 2022.
View our earnings forecast for Mersana Therapeutics

How were Mersana Therapeutics' earnings last quarter?

Mersana Therapeutics, Inc. (NASDAQ:MRSN) posted its earnings results on Monday, May, 9th. The company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.31) by $0.28. Mersana Therapeutics had a negative net margin of 8,826.73% and a negative trailing twelve-month return on equity of 119.10%. During the same quarter last year, the firm posted ($0.50) EPS.
View Mersana Therapeutics' earnings history

Who are Mersana Therapeutics' key executives?

Mersana Therapeutics' management team includes the following people:
  • Ms. Anna Protopapas M.B.A., Pres, CEO & Director (Age 58, Pay $852.34k) (LinkedIn Profile)
  • Mr. Brian C. DeSchuytner, Sr. VP & CFO (Age 44, Pay $570.49k)
  • Dr. Timothy B. Lowinger Ph.D., Chief Science & Technology Officer (Age 58, Pay $598.29k) (LinkedIn Profile)
  • Ms. Alejandra Veronica Carvajal J.D., SVP, Sec. & Chief Legal Officer (Age 48, Pay $511.29k)
  • Dr. Tushar Misra Ph.D., SVP & Chief Manufacturing Officer (Age 62, Pay $485.89k)
  • Mr. Mikhail Papisov Ph.D., Co-Founder
  • Mr. Ashish Mandelia, VP, Controller & Principal Accounting Officer (Age 48) (LinkedIn Profile)
  • Ms. Sarah Carmody, Exec. Director of Investor Relations & Corp. Communications
  • Ms. Carla Poulson, Chief People Officer
  • Mr. Chuck Miller, Sr. VP of Regulatory Affairs

What is Anna Protopapas' approval rating as Mersana Therapeutics' CEO?

3 employees have rated Mersana Therapeutics CEO Anna Protopapas on Glassdoor.com. Anna Protopapas has an approval rating of 100% among Mersana Therapeutics' employees. This puts Anna Protopapas in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Mersana Therapeutics own?

When did Mersana Therapeutics IPO?

(MRSN) raised $75 million in an IPO on Wednesday, June 28th 2017. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Cowen and Leerink Partners served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Mersana Therapeutics' stock symbol?

Mersana Therapeutics trades on the NASDAQ under the ticker symbol "MRSN."

Who are Mersana Therapeutics' major shareholders?

Mersana Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (9.15%), Bellevue Group AG (4.08%), Rock Springs Capital Management LP (3.87%), Vanguard Group Inc. (3.54%), Artal Group S.A. (2.64%) and Candriam Luxembourg S.C.A. (1.90%). Company insiders that own Mersana Therapeutics stock include Alejandra Carvajal, Andrew A F Hack, Anna Protopapas, Arvin Yang, Ashish Mandelia, Eva M Jack, Lawrence M Alleva, Lawrence M Alleva, Scott D Sandell and Timothy B Lowinger.
View institutional ownership trends for Mersana Therapeutics

Which institutional investors are selling Mersana Therapeutics stock?

MRSN stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, State Street Corp, Citigroup Inc., Bellevue Group AG, Candriam Luxembourg S.C.A., Vanguard Group Inc., UBS Group AG, and Allianz Asset Management GmbH. Company insiders that have sold Mersana Therapeutics company stock in the last two years include Alejandra Carvajal, Anna Protopapas, Arvin Yang, Ashish Mandelia, Eva M Jack, and Timothy B Lowinger.
View insider buying and selling activity for Mersana Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Mersana Therapeutics stock?

MRSN stock was acquired by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Artal Group S.A., Decheng Capital Management III Cayman LLC, Renaissance Technologies LLC, Federated Hermes Inc., Rock Springs Capital Management LP, Goldman Sachs Group Inc., and Pinz Capital Management LP. Company insiders that have bought Mersana Therapeutics stock in the last two years include Andrew A F Hack, and Lawrence M Alleva.
View insider buying and selling activity for Mersana Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Mersana Therapeutics?

Shares of MRSN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Mersana Therapeutics' stock price today?

One share of MRSN stock can currently be purchased for approximately $5.00.

How much money does Mersana Therapeutics make?

Mersana Therapeutics (NASDAQ:MRSN) has a market capitalization of $484.95 million and generates $40 thousand in revenue each year. The company earns $-170.06 million in net income (profit) each year or ($2.490010) on an earnings per share basis.

How many employees does Mersana Therapeutics have?

Mersana Therapeutics employs 169 workers across the globe.

How can I contact Mersana Therapeutics?

Mersana Therapeutics' mailing address is 840 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The official website for Mersana Therapeutics is www.mersana.com. The company can be reached via phone at (617) 498-0020 or via email at [email protected].

This page (NASDAQ:MRSN) was last updated on 6/25/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.